Floatz logo

Alv-100

Overweight or Obese, Type 2 Diabetes

Alveus Therapeutics, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Overweight or Obese, Type 2 Diabetes cohort.

Asset / SponsorPhaseRating
hrs9531
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 1CC

Same molecule, other indications

Alv-100 is also rated in:

obesity disorderDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →